| Literature DB >> 30212476 |
Sanjeev Chawla1,2, Ilya Kister3, Tim Sinnecker4, Jens Wuerfel4, Jean-Christophe Brisset1, Friedemann Paul5,6, Yulin Ge1.
Abstract
Pathophysiology of multiple sclerosis (MS) lesions is dynamic and changes over time. The purpose of this exploratory study was to determine the longitudinal changes in MS lesions over time on ultra-high field MR imaging. Nine patients with MS underwent high-resolution 3D-susceptibility weighted imaging (SWI) and 2D-gradient-echo-T2*-weighted imaging on 7T MRI at baseline and after ~2.4 years of follow-up. Morphologic imaging characteristics, signal intensity patterns and quantitative susceptibility mapping (QSM) values of lesions were recorded at both time points. Lesions were classified as "iron-laden" if they demonstrated hypointense signal on T2*-weighted images and/or SWI as well as hyperintense signal on QSM. Lesions were considered "non-iron-laden" if they were hyperintense on T2*/SWI and isointense or hyperintense on QSM. Total of 162 non-iron-laden and 29 iron-laden lesions were observed at baseline. No change in baseline lesion size during follow up was recorded in 92.7%; no change in lesion-vessel relationship in 86.5%; and no change in signal intensity pattern in 96.9% of lesions. Three lesions which were non-iron-laden at baseline, exhibited iron at follow-up. In two iron-laden lesions, redistribution of iron content was observed at follow-up. Two-thirds of these iron-laden lesions showed an increase in QSM at follow-up relative to baseline, and the remaining one-third exhibited decrease in QSM. Most of the newly formed lesions (11/13, 84.6%) at follow-up were iron-laden. 7T multiparametric MRI is a useful tool for tracking the evolution of MS lesions, especially with regard to changes in iron content.Entities:
Mesh:
Year: 2018 PMID: 30212476 PMCID: PMC6136714 DOI: 10.1371/journal.pone.0202918
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Demographics of MS patients.
| ID | Age | M/F | Race | Disease Type | Disease Duration | EDSS | DMT | Time between baseline and Follow up MRI (Years) | Number of Lesions at Baseline | Number of Lesions at Follow-up |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 67.7 | F | AA | PPMS | 11 | 6 | Cyclophosph-amide | 2.43 | 67 | 67 |
| 2 | 48.9 | M | AA | SPMS | 14 | 2 | No DMT | 2.46 | 15 | 25 |
| 3 | 72.8 | F | AA | SPMS | 15 | 2 | Glatiramer- acetate | 2.03 | 13 | 13 |
| 4 | 48.0 | F | His | RRMS | 7 | 1 | No DMT | 2.06 | 19 | 19 |
| 5 | 36.0 | M | CAU | RRMS | 13 | 4 | Dimethyl fumarate | 2.26 | 2 | 2 |
| 6 | 40.8 | F | CAU | RRMS | 12 | 1 | Fingolimod | 2.00 | 21 | 21 |
| 7 | 70.4 | F | CAU | SPMS | 48 | 7 | Natalizumab | 2.39 | 17 | 17 |
| 8 | 55.9 | F | AA | SPMS | 12 | 6 | Dimethyl fumarate | 3.83 | 16 | 17 |
| 9 | 48.0 | F | CAU | RRMS | 9 | 1 | Rituximab | 2.09 | 21 | 23 |
M = Male; F = Female; AA = African-American; His = Hispanic; CAU = Caucasian; PPMS = Primary Progressive MS; SPMS = Secondary Progressive MS; RRMS = Relapsing-Remitting MS; EDSS = Expanded Disability Status Scale; DMT = Disease Modifying Therapy
Proposed histopathologic interpretation based upon signal intensity patterns on MR images.
| Tissue Content | Susceptibility Effect | Signal Intensity on GRE-T2* | Signal Intensity on SWI | Signal Intensity on QSM |
|---|---|---|---|---|
| Calcium | Diamagnetism | Hypointense | Hypointense | Hypointense |
| Myelin | Diamagnetism | Isointense | Isointense | Isointense |
| Variable degree of micronecrosis, edema, gliosis, demyelination and macromolecules | Diamagnetism | Hyperintense | Isointense or | Isointense |
| Extensive degree of demyelination | Loss of diamagnetism (paramagnetism) | Hyperintense | Isointense or | Hyperintense |
| Iron | Paramagnetism | Hypointense | Hypointense | Hyperintense |
GRE = Gradient Echo; SWI = Susceptibility Weighted Imaging; QSM = Quantitative Susceptibility Mapping
Distribution of iron-laden and non-iron-laden lesions at baseline, pattern switch and formation of new lesions by disease type.
| Patient ID | Disease Type | Number of Iron-laden Lesions | Number of Non Iron-laden Lesions | Total Number of Lesions |
| 1 | PPMS | 1 | 66 | 67 |
| 2 | SPMS | 12 | 3 | 15 |
| 3 | SPMS | 0 | 13 | 13 |
| 4 | RRMS | 0 | 19 | 19 |
| 5 | RRMS | 0 | 2 | 2 |
| 6 | RRMS | 0 | 21 | 21 |
| 7 | SPMS | 1 | 16 | 17 |
| 8 | SPMS | 13 | 3 | 16 |
| 9 | RRMS | 2 | 19 | 21 |
| Patient ID | Disease Type | Lesion Pattern at Baseline | Lesion Pattern at Follow-up | |
| 2 | SPMS | A | C | |
| 2 | SPMS | A | C | |
| 2 | SPMS | C | D | |
| 4 | RRMS | B | A | |
| 6 | RRMS | A | C | |
| 8 | SPMS | D | C | |
| Patient ID | Disease Type | Iron-laden Lesion | Non-iron-laden Lesion | |
| 2 | SPMS | 10 | 0 | |
| 8 | SPMS | 1 | 0 | |
| 9 | RRMS | 0 | 2 | |
PPMS = Primary Progressive MS; SPMS = Secondary Progressive MS; RRMS = Relapsing-Remitting MS